Abstract
Background Constrictive pericarditis (CP) is an uncommon but reversible cause of diastolic heart failure if appropriately identified and treated. Although echocardiography can detect CP based on characteristic cardiac motion and Doppler findings, its diagnosis remains a challenge for clinicians. Artificial intelligence (AI) may enhance identification of CP. We proposed a deep learning approach based on transthoracic echocardiography (TTE) to differentiate CP from restrictive cardiomyopathy (RCM).
Methods Patients with a confirmed diagnosis of CP and cardiac amyloidosis (CA, as the representative disease of RCM) at Mayo Clinic Rochester from 1/2003-12/2021 were identified to extract baseline demographics and the apical 4 chamber (A4C) view from TTE studies. The cases were split into a 60:20:20 ratio for training, validation, and held-out test sets of the ResNet50 deep learning model. The model performance (differentiating CP and CA) was evaluated in the test set with the area under the curve (AUC). GradCAM was used for model interpretation.
Results A total of 381 patients were identified, including 184 (48.3%) CP, and 197 (51.7%) CA cases. The mean age was 68.7±11.4, and 72.8% were male. ResNet50 had a performance with an AUC to differentiate the 2-class classification task (CP vs. CA, AUC 0.97). The GradCAM heatmap showed activation around the ventricular septal area.
Conclusion With a standard A4C view, our AI model provides a platform for the early and accurate detection of CP, allowing for improved workflow efficiency and prompt referral for more advanced evaluation and intervention of CP.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Mayo Clinic IRB; protocol#19-009303
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Financial Disclosure: None.
Data Availability
All data produced in the present work are contained in the manuscript
Abbreviations
- A4C
- apical 4 chamber view
- AI
- Artificial Intelligence
- AUC
- area under the curve
- CA
- cardiac amyloidosis
- CP
- constrictive pericarditis
- RCM
- restrictive cardiomyopathy
- TTE
- transthoracic echocardiography
